Provident Investment Management’s AbbVie ABBV Stock Holding History

Provident Investment Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-5,977	Closed	-$1.37M	–	83
2025 Q4	$1.37M	Sell	5,977 -30	-0.5%	-$6.83K	0.12%	38
2025 Q3	$1.39M	Buy	6,007 +70	+1%	+$14.3K	0.12%	33
2025 Q2	$1.1M	Buy	5,937 +950	+19%	+$177K	0.09%	38
2025 Q1	$1.04M	Sell	4,987 -65	-1%	-$12.6K	0.1%	37
2024 Q4	$898K	Buy	5,052 +115	+2%	+$21.1K	0.09%	43
2024 Q3	$975K	Buy	4,937 +369	+8%	+$68.9K	0.09%	36
2024 Q2	$784K	Buy	4,568 +265	+6%	+$43.9K	0.07%	44
2024 Q1	$784K	Buy	4,303 +608	+16%	+$105K	0.07%	41
2023 Q4	$573K	Buy	3,695 +388	+12%	+$56.6K	0.05%	48
2023 Q3	$493K	Buy	3,307 +512	+18%	+$75.2K	0.05%	47
2023 Q2	$377K	Buy	2,795 +626	+29%	+$91.8K	0.04%	58
2023 Q1	$346K	Buy	+2,169	New	+$332K	0.04%	56
2017 Q1	–	Sell	-4,317	Closed	-$270K	–	51
2016 Q4	$270K	Hold	4,317	–	–	0.05%	48
2016 Q3	$272K	Hold	4,317	–	–	0.06%	48
2016 Q2	$267K	Hold	4,317	–	–	0.06%	49
2016 Q1	$247K	Buy	+4,317	New	+$241K	0.05%	53

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Provident Investment Management's ABBV Position: Q1 2026 in Review

Provident Investment Management sold out of AbbVie (ABBV) in Q1 2026, closing a stake of 5,977 shares — an estimated $1.37M sold.

Provident Investment Management first reported a position in ABBV in Q1 2016 and held it in 16 quarters. The position peaked at $1.39M in Q3 2025. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Provident Investment Management reported no remaining AbbVie position as of Q1 2026 after selling out during the quarter.
Provident Investment Management sold 5,977 AbbVie shares in Q1 2026, an estimated $1.37M.
Provident Investment Management first reported a position in AbbVie in Q1 2016 and held it in 16 quarters.
Provident Investment Management's AbbVie position peaked at $1.39M in Q3 2025.
4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Provident Investment Management's 13F filing for Q1 2026, filed 13 May 2026.